Adult dose and duration0.100 mg (100 micrograms) of estradiol daily by transdermal patch or vaginal ring - the article's regimen, and the routes it prefers. The Egyptian formulary's oral figure, for comparison, is estradiol valerate 1 mg daily, increased to 2 mg if needed. - Until the average age of natural menopause - the article's figure is 50.5 years
Paediatric doseNot a paediatric prescription. Adolescents with primary ovarian insufficiency (Turner syndrome, for example) need induction of puberty on a paediatric-endocrine schedule, which no document held here states.
Dose sourcePremature ovarian insufficiency - disease-level clinical article (premature-ovarian-insufficiency-full.txt), which states the transdermal/transvaginal dose and the duration, with the oral figure and the contraindication block from Egyptian National Drug Formulary - Endocrine System 2024 (estradiol monograph)
WhyThe card carried no oestrogen at all, which is why the earlier attempt to add the progestogen the article calls imperative could not stand - it would have been an adjunct to nothing. The article states the indication, the dose, the route and the duration in one place: estradiol (17B-E2) replacement is the mainstay for POI, given transvaginally or by transdermal patch, both of which lower the overall venous thromboembolism risk against oral replacement; a vaginal ring, or a patch, puts out 0.100 milligrams of estradiol a day. The international figure leads and the Egyptian formulary's oral 1-2 mg is noted beside it - and here the difference is route, not strength: the article prefers the non-oral routes for a stated reason (VTE). Egypt registers the matching patch (FEM 7 100 mcg, 50 EGP) as well as 50 and 75 mcg strengths.
Cautions- GIVEN WITH a progestogen whenever the uterus is intact. The formulary puts it on the oestradiol monograph itself: where the uterus is still there, a progestogen goes alongside the oestradiol, for 12 to 14 days at the least, in every 28-day cycle, begun on the first day of the bleed. Oestrogen on its own is appropriate only for a woman who has had a hysterectomy.
- CONTRAINDICATED - the formulary bars it in: endometrial hyperplasia that has not been treated; breast cancer, known or suspected; an oestrogen-dependent tumour; genital bleeding that has not been explained; deep vein thrombosis or pulmonary embolism, whether active now or in the past; and recent arterial thromboembolic disease. On the liver: it is contraindicated where hepatic function is actively disturbed.
- Why replace at all - the article's case for oestrogen replacement in POI: it takes away the vasomotor symptoms, keeps bone density up and fracture risk down, lowers illness and death from cardiovascular and autoimmune causes, guards cognition, and leaves the woman better in herself overall.
- The target - treatment aims to hold the oestradiol at 100 pg/mL day by day, the level a premenopausal woman with working ovaries runs at. This is replacement to a normal premenopausal level, not menopausal symptom control, and the dose is higher than a postmenopausal HRT dose for that reason.
- A combined oral contraceptive is NOT an equivalent substitute. It carries more venous thromboembolism than replacement does, and it fails to deliver the daily physiological level the woman needs.
- Started and monitored by gynaecology or endocrinology. This row exists so the regimen and its requirements are visible in primary care, and so that a woman already on it is not left without it.
- The Egyptian product this row means is the FEM 7 transdermal patch, registered at 50, 75 and 100 micrograms. The route is recorded as topical because the register files patches without a route and that is what finds them; it is a skin patch, not a cream. Two other products file under the same ingredient name and are deliberately excluded from this row - ETHINYL OESTRADIOL tablets (a different molecule, the contraceptive oestrogen) and FOLONE oily ampoules (an intramuscular depot).